Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
US11110054B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2018 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Oct 25, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/183
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.